A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: Results of the RADAR trial

European Heart Journal

Volumn 34, Issue 31, 2013, Pages 2481-2489

  Povsic, Thomas J ^a   Vavalle, John P ^a   Aberle, Laura H ^a   Kasprzak, Jaroslaw D ^b   Cohen, Mauricio G ^c   Mehran, Roxana ^d   Bode, Christoph ^e   Buller, Christopher E ^f   Montalescot, Gilles ^g   Cornel, Jan H ^h   Rynkiewicz, Andrzej ⁱ   Ring, Michael E ^j   Zeymer, Uwe ^k   Natarajan, Madhu ^l   Delarche, Nicolas ^m   Zelenkofske, Steven L ⁿ   Becker, Richard C ^a   Alexander, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e TU BERGAKADEMIE FREIBERG   (Germany)

^f HAMILTON GENERAL HOSPITAL   (Canada)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Northwest Clinics   (Netherlands)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j SACRED HEART MEDICAL CENTER   (United States)

^k Heart Center Ludwigshafen   (Germany)

^l HAMILTON HEALTH SCIENCES   (Canada)

^m Service de Radiologie   (France)

ⁿ Regado Biosciences   (United States)

more..

Author keywords

Acute coronary syndromes; Anticoagulation reversal; REG1

Indexed keywords

ACETYLSALICYLIC ACID; ANIVAMERSEN; CLOPIDOGREL; CREATINE KINASE MB; HEPARIN; PEGNIVACOGIN; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; ALLERGIC URTICARIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SHEATH REMOVAL; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROMES; ANTICOAGULATION REVERSAL; REG1;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; CARDIAC CATHETERIZATION; COAGULANTS; FACTOR IXA; FEASIBILITY STUDIES; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; OLIGONUCLEOTIDES; RECURRENCE; TREATMENT OUTCOME;

EID: 84866743368     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs232     Document Type: Article

References (30)

1. Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development, and clinical application. Thromb Haemost 2005;93:1014-1020.
2. Becker RC, Povsic TJ, Cohen MG, Rusconi CP, Sullenger BA. Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost 2010;103:586-595.
3. Povsic T, Sullenger B, Zelenkofske S, Rusconi C, Becker R. Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. J Cardiovasc Transl Res 2011;3:704-716.
4. Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA, Alexander JH, Rusconi CP, Becker RC. Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. J Thromb Thrombolysis 2011;32:21-31.
5. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114:2490-2497.
6. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorcheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117:2865-2874.
7. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC. A randomized, repeat-dose, pharmacodynamic and safety study of an antidotecontrolled factor IXa inhibitor. J Thromb Haemost 2008;6:789-796.
8. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous intervention. Circulation 2010;122:614-622.
9. Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, Alexander JH. A randomized, partially-blinded, multicenter, activecontrolled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR phase IIb trial. Am Heart J 2011; 161:261-268.
10. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J 2011; 32:2412-2419.
11. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite synergistic effects of factors XI and XII. Blood 2006;108:4045-4051.
12. Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP. Relationship between markers of activated coagulation, their correlation with inflammation, and association with heart disease (NPHSII). J Thromb Haemost 2008;6:259-267.
13. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009; 374:787-795.
14. Eriksson BI, Dahl OE, Lassen MR, Ward DP, Rothlein R, Davis G, Turpie AG. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 2008;6:457-463.
15. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagul Fibrinolysis 1996;7: 459-464.
16. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
17. Cantor WJ, Mahaffey KW, Huang Z, Das P, Gulba DC, Glezer S, Gallo R, Ducas J, Cohen M, Antman EM, Langer A, Kleiman NS, White HD, Chisholm RJ, Harrington RA, Ferguson JJ, Califf RM, Goodman SG. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Intervent 2007;69:73-83.
18. Gallo R, Steinhubl SR, White HD, Montalescot G. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial. Catheter Cardiovasc Intervent 2009;73:319-325.
19. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, Chuang YC, Clark C, Merritt AJ, Bucher TA, Leon MB. Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-1578.
20. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291:350-357.
21. Vaitkus PT. A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention. J Invasive Cardiol 2004;16:243-246.
22. Biancari F, D'Andrea V, Marco CD, Savino G, Tiozzo V, Catania A. Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty. Am Heart J 2010;159:518-531.
23. Mercuri M, Mehta S, Xie C, Valettas N, Velianou JL, Natarajan MK. Radial artery access as a predictor of increased radiation exposure during a diagnostic cardiac catheterization procedure. JACC Cardiovasc Interv 2011;4:347-352.
24. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, Budaj A, Niemelä M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377: 1409-1420.
25. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against Poly(ethylene glucol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2005;8:R12.
26. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56:1021-1028.
27. Sundy JS, Hershfield Michael S. Uricase and other novel agents for the management of patients with treament-failure gout. Curr Rheumatol Rep 2007;9:258-264.
28. Steg PG, Mehta SR, Jukem JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB. RUBY-1: a randomized, doubleblind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM15)) following acute coronary syndrome. Eur Heart J 2011;32:2541-2554.
29. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230.
30. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.